Patents by Inventor Edwin Schweiger
Edwin Schweiger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8703805Abstract: Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: GrantFiled: June 26, 2006Date of Patent: April 22, 2014Assignee: Exelixis Patent Company LLCInventors: Brett B. Busch, Brenton T. Flatt, Xiao Hui Gu, Shao Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin Schweiger, William C. Stevens, Jr., Tie Lin Wang, Yinong Xie
-
Patent number: 8569352Abstract: Compounds of the invention, such as compounds of Formulae IIa, IIb, IIc or IId, and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3 and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: GrantFiled: June 26, 2006Date of Patent: October 29, 2013Assignee: Exelixis Patent Company LLCInventors: Brett B. Busch, Brenton T. Flatt, Xiao-Hui Gu, Shao-Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin Schweiger, William C. Stevens, Jr., Tie-Lin Wang, Yinong Xie
-
Patent number: 8163771Abstract: A compound according to Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R11, L1 and X are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.Type: GrantFiled: March 13, 2009Date of Patent: April 24, 2012Assignee: Exelixis, Inc.Inventors: Richard Martin, Brenton T. Flatt, Jackline Eve Dalgard, Venkataiah Bollu, Ping Huang, Raju Mohan, Edwin Schweiger, Tie-Lin Wang
-
Patent number: 7998995Abstract: Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: GrantFiled: December 7, 2007Date of Patent: August 16, 2011Assignee: Exelixis Patent Company LLCInventors: Brant Clayton Boren, Brett B. Busch, Xiao-Hui Gu, Vasu Jammalamadaka, Shao Po Lu, Richard Martin, Raju Mohan, Edwin Schweiger, William C. Stevens, Tie-Lin Wang, Yinong Xie, Wei Xu
-
Publication number: 20100331295Abstract: Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: ApplicationFiled: June 26, 2006Publication date: December 30, 2010Applicant: EXELIXIS, INC.Inventors: Brett B Busch, Brenton T. Flatt, Xiao Hui Gu, Shao Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin Schweiger, William C. Stevens, JR., Tie Lin Wang, Yinong Xie
-
Publication number: 20100105675Abstract: A compound according to Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R11, L1 and X are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: March 13, 2009Publication date: April 29, 2010Applicant: Exelixis, Inc.Inventors: Richard Martin, Brenton Flatt, Jackline Dalgard, Venkataiah Bollu, Ping Huang, Raju Mohan, Edwin Schweiger, Tie Lin Wang
-
Publication number: 20100075964Abstract: Compounds of the invention, such as compounds of Formulae IIa, IIb, IIc or IId, and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3 and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: ApplicationFiled: June 26, 2006Publication date: March 25, 2010Applicant: EXELIXIS, INC.Inventors: Brett B. Busch, Brenton T. Flatt, Xiao-Hui Gu, Shao-Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin Schweiger, William C. Stevens, Jr., Tie-Lin Wang, Yinong Xie
-
Publication number: 20100069367Abstract: Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: ApplicationFiled: December 7, 2007Publication date: March 18, 2010Applicant: EXELIXIS, INC.Inventors: Brant Clayton Boren, Brett B. Busch, Xiao-Hui Gu, Vasu Jammalamadaka, Shao Po Lu, Richard Martin, Raju Mohan, Edwin Schweiger, William C. Stevens, Tie-Lin Wang, Yinong Xie, Wei Xu
-
Publication number: 20090247515Abstract: A compound according to Formula A: or a pharmaceutically acceptable salt thereof, wherein R11, G1 and G2 are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: March 13, 2009Publication date: October 1, 2009Applicant: Exelixis, Inc.Inventors: Richard Martin, Brenton T. Flatt, Jackline Eve Dalgard, Venkataiah Bollu, Ping Huang, Raju Mohan, Edwin Schweiger, Tie-Lin Wang
-
Publication number: 20050080111Abstract: Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: ApplicationFiled: July 24, 2004Publication date: April 14, 2005Applicant: X-Ceptor Therapeutics, Inc.Inventors: Christopher Bayne, Alan Johnson, Shao-Po Lu, Raju Mohan, Michael Nyman, Edwin Schweiger, William Stevens, Haixia Wang, Yinong Xie
-
Patent number: 6774138Abstract: In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. The ring additionally includes three, four or five atoms independently selected from carbon, nitrogen, sulfur and oxygen atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon double bond, a carbon-carbon triple bond or an azo group. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system.Type: GrantFiled: August 13, 2002Date of Patent: August 10, 2004Assignee: Merck & Co., Inc.Inventors: Nicholas David Peter Cosford, Leo Solomon Bleicher, Jean-Michel Andre Vernier, Rowena V. Cube, Edwin Schweiger, Ian McDonald